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Abstract
Objectives—To determine whether data obtained from the medical literature can be used to 
estimate the therapeutic index of 5 antiepileptic drugs (AEDs): carbamazepine, lamotrigine, 
phenobarbital, phenytoin, and valproate.
Methods—We performed a literature search using PubMed and Embase to collect published 
safety, efficacy, and therapeutic monitoring data for 5 AEDs, and extracted all relevant information 
into a drug- and study-specific drug database. For each AED, we summarized: 1) type, severity, 
and incidence of toxicity-related adverse events and toxicity-associated range of drug doses or 
concentrations; 2) effective versus toxic concentration and dose (therapeutic range); and 3) 
therapeutic drug monitoring practices. We defined therapeutic index as the ratio of the minimum 
toxic concentration to the minimum effective concentration.
Results—We reviewed a total of 810 full-text articles and extracted data from 163. The literature 
suggests that the therapeutic index of phenytoin is 2. The therapeutic indices of phenobarbital and 
valproate exceed 2. There was insufficient data to precisely quantify the therapeutic indices of 
carbamazepine and lamotrigine.
Conclusions—For some drugs, this approach offers a low-cost method of therapeutic index 
estimation. Our results can serve as preliminary data for future trials, and as guidance for FDA 
decision-making regarding narrow therapeutic index classification.
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INTRODUCTION
Over 150 generic antiepileptic drug (AED) formulations have been approved by the US 
Food and Drug Administration (FDA).1 In order to market a generic version of any drug, the 
sponsor must provide evidence of pharmaceutical equivalence and bioequivalence between 
the brand-name and the generic drug. In 2010, the FDA proposed that certain drugs 
classified as having a narrow therapeutic index (NTI) should achieve more stringent 
regulatory standards for approval.2 NTI drugs generally have the following characteristics: 
(a) there is little separation between therapeutic and toxic doses (or the associated blood/
plasma concentrations); (b) sub-therapeutic concentrations may lead to serious therapeutic 
failure; (c) they are subject to therapeutic monitoring based on pharmacokinetic (PK) or 
pharmacodynamic (PD) measures; (d) they possess low-to-moderate (i.e., no more than 
30%), within-subject variability; and (e) doses are often adjusted in very small increments 
(less than 20%) in clinical practice. For generic drugs classified as NTI, the proposed 
bioequivalence criteria require the use of reference-scaled testing and variability 
comparison, which makes these criteria tighter than the traditional average bioequivalence 
criteria.2–4
For these new standards to be implemented, it is critical to define which drugs can be 
classified as NTI. Conversion from brand-name to generic formulations of AEDs has been 
associated with increased frequency of seizures and adverse effects, which has led to a lack 
of confidence by some providers and patients in generic products.5–8 If certain AEDs could 
be identified as NTI drugs, application of the new criteria to the development of generic 
formulations could improve patient safety, enhance physician confidence in generic 
products, and result in overall cost savings due to increased generic drug prescribing. NTI 
classification requires therapeutic index estimation, which is not well-established for many 
generic AEDs. The purpose of our study was to determine whether data obtained from an 
exhaustive search of the medical literature could be used to estimate the therapeutic index of 
5 off-patent AEDs.
MATERIALS AND METHODS
Through collaboration with the FDA, review of international regulatory agency websites 
(including Health Canada,9 the European Medicines Agency,10 and the National Institute of 
Health Sciences-Japan11), and consultation with neurology therapeutic experts, we identified 
the 5 AEDs as potential NTI drugs requiring closer evaluation to determine if they may 
benefit from tighter bioequivalence standards for generic drug development. carbamazepine, 
lamotrigine, phenobarbital, phenytoin, and valproate.
Literature search
For each of the 5 AEDs, we performed an exhaustive literature search of all available 
indexed articles using Pubmed and Embase. We did not limit our search to a particular time 
period. The search was conducted with the aid of professional librarians from Duke 
University Medical Library (Figure 1). We reviewed abstracts for all articles identified by 
the search to determine whether they might contain relevant data focused on: 1) efficacy 
and/or safety data from prospective randomized controlled trials in the labeled indication for 
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the drug; 2) therapeutic drug range and/or monitoring; or 3) adult PK data. Full text articles 
were reviewed for all abstracts of potential interest, and data was extracted into a drug- and 
study-specific drug database. Specific variables extracted included: study demographics, 
drug dosing and formulation, PK parameters (e.g., maximum concentration (Cmax), area 
under the curve (AUC), clearance, half-life (t1/2)), and efficacy data (study phase, primary 
outcome, and study result). Among safety data, we collected black box warnings and 
precautions indicated on the drug label, and all adverse events (AEs) with a placebo-adjusted 
frequency >10%. When it was uncertain whether data should be included, the manuscript 
was reviewed by a second study team member to reach consensus. As a quality assurance 
measure, 5% of the extracted data underwent an independent full review by 1 reviewer.
Therapeutic index estimation
For each AED, we summarized by patient population: 1) type, severity, and incidence of 
toxicity-related AEs and toxicity-associated range of drug doses and concentrations; and 2) 
effective versus toxic concentration and dose (therapeutic range). To determine the 
therapeutic index of each drug, we aimed to determine the concentration of drug associated 
with selected AEs in approximately 50% of the population (TC50) and the concentration 
associated with efficacy in approximately 50% of the population (EC50). We defined the 
therapeutic index as TC50 divided by EC50. However, in the absence of available data in the 
literature to calculate TC50 and EC50, we defined therapeutic index as the ratio of the 
minimum toxic concentration to the minimum effective concentration.12,13 Even though the 
FDA does not specify a threshold value to determine whether a therapeutic index is narrow, 
in this study we considered a therapeutic index ≤2 as one criterion to support classification 
as an NTI drug.12,13
RESULTS
Carbamazepine
Safety—AEs associated with carbamazepine use in patients with epilepsy include 
somnolence, dizziness, gastrointestinal disturbance, and hematologic abnormalities (Table 
1).14–22 There were conflicting results regarding the relationship between systemic exposure 
and toxicity. Several studies demonstrated that the prevalence of carbamazepine AEs was 
concentration-related, with toxicity occurring at concentrations >8. 7–11. 8 μg/mL.23–28 
Conversely, other studies found no significant difference in mean carbamazepine serum 
concentrations between patients with and without AEs.18,19
Efficacy—Carbamazepine efficacy with mono- and combination therapy was assessed in 
studies using 3 different measures: 1) percentage of patients with a ≥50% reduction in 
seizures; 2) reduction in total seizures during the study period; and 3) percentage of patients 
who were seizure-free in specific time periods (Table 2).14, 17, 18, 20, 21 Only one study 
reported a positive correlation between carbamazepine concentration and seizure control.22
Therapeutic range and drug monitoring—The conventionally accepted therapeutic 
range of plasma concentrations of carbamazepine in adults is 4–12 μg/mL.29 The dose range 
associated with efficacy and toxicity partially overlaps. Serum concentrations associated 
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with efficacy range between 1.9 and 11.7 μg/mL, though concentrations less than 4 μg/mL 
result in less optimal seizure control in the overall epilepsy population.22,30,31 AEs have 
been reported in carbamazepine concentrations ranging from 4–19. 6 μg/mL, and higher 
concentrations are generally associated with more AEs.24,28,32–34
In clinical practice, therapeutic drug monitoring (TDM) is often not routinely performed for 
carbamazepine, though there is variability among clinicians. Drug levels may be checked 
when patients experience adverse effects or experience break-through seizures, and to 
monitor compliance with therapy. Patients taking interacting medications or patients 
converting from one drug formulation to another may require TDM.
Therapeutic index estimation—Information from the medical literature generally 
supports the accepted carbamazepine therapeutic range of 4–12 μg/mL. However, the 
response to carbamazepine therapy is reportedly variable, and patients may require lower or 
higher serum concentrations to achieve adequate seizure control. The available information 
suggests an approximate carbamazepine therapeutic index of 3. However, TDM may be 
required for patient safety in certain settings, such as when a patient experiences an adverse 
effect or break-through seizures. Further data, other than literature reviews, are needed to 
determine whether carbamazepine may require stricter bioequivalence criteria in these 
instances.
Lamotrigine
Safety—AEs associated with lamotrigine use in patients with refractory seizure occur in 
dose ranges of 100–500 mg/day (Table 1).35–40 The prevalence of AEs with lamotrigine use 
has been shown to be dose-related and generally independent of concomitantly administered 
medications.41 However, co-administration of valproate with lamotrigine has been 
associated with skin rash.42 Moreover, the fraction of subjects necessitating dose 
modification or discontinuation increased by 25% when plasma levels exceeded 20 μg/mL.41
Efficacy—Lamotrigine efficacy with mono- and combination therapy was assessed in 
studies using 3 different measures: 1) percentage of patients who had a >50% reduction in 
seizures; 2) reduction in total seizures during the study period; and 3) percentage of patients 
with seizure freedom in a specific time period (Table 2).18,19,37,43,44
Therapeutic range and drug monitoring—The dose range associated with efficacy 
and toxicity partially overlaps. In a large-scale observational study (N=811), overall toxicity 
of lamotrigine increased gradually with increasing serum concentrations, whereas efficacy of 
lamotrigine did not correlate with serum levels when the concentration of lamotrigine was 
below 15 μg/mL.41 In this study, about 50% of the population was seizure-free at 6 months 
at levels ranging from 1–15 μg/mL. The therapeutic index calculated based on the available 
data for lamotrigine was in the range of 1.3–20. In clinical practice, TDM is not routinely 
performed for lamotrigine. However, the American Academy of Neurology recommends 
that TDM of lamotrigine should be considered in pregnant women with epilepsy because 
pregnancy causes an increase in the clearance and a decrease in the level of lamotrigine.45,46 
Due to the widely varying doses of lamotrigine, there is no well-defined one-size-fits-all 
Greenberg et al. Page 4
Clin Neuropharmacol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
target range in these patients. Individualized dosing or target concentrations are determined 
by attending physicians based on a range of other parameters including response, severity of 
symptoms, other drugs, and side effects.47
Therapeutic index estimation—Based on literature data, the therapeutic range of 
lamotrigine is not well established, nor is there a clear dose-to-response curve for safety or 
efficacy. The therapeutic index determined from the medical literature extends from a value 
on the border of supporting classification of the therapeutic index as narrow to a ten-fold 
higher value that would not be consistent with the therapeutic index being narrow (Table 3). 
Due to this uncertainty, our method of estimating the therapeutic index was unable to 
distinguish whether the therapeutic index of lamotrigine should be determined as narrow.
Phenobarbital
Safety—AEs associated with phenobarbital use occur at a wide range of doses (Table 
1).48–51 In a single study evaluating the relationship between dose or plasma concentration 
and development of an AE, most AEs occurred in subjects with total serum phenobarbital 
levels at or below the standard accepted therapeutic range of 15–40 μg mL.51 The 
investigators did not find a relationship between phenobarbital levels and occurrence of AEs; 
however, there was a significant relationship between the number of concomitant 
antiepileptic agents (i.e., phenytoin, carbamazepine, and benzodiazepines) and occurrence of 
AEs.
Efficacy—Phenobarbital efficacy with mono- and combination therapy was assessed in 
studies using 3 different measures: 1) reduction in seizure frequency; 2) achievement of 
seizure remission for a predefined period of time; and 3) percentage of patients with 
treatment failure (Table 2).
Therapeutic range and drug monitoring—The conventional therapeutic range for 
phenobarbital is 15–40 μg/mL.52 In the vast majority of available studies, phenobarbital 
functioned as an active control or an adjunct drug in the study of other antiepileptic agents 
and was noted to be efficacious when serum concentrations were within the stated 
therapeutic range.31,53–57 In addition, it has been reported that some subjects have remained 
seizure-free at phenobarbital levels well below 10 μg/mL,52 while clearly other subjects can 
have seizures refractory to phenobarbital therapy despite levels in the therapeutic range.58
In clinical practice, TDM is routinely performed for phenobarbital.52 However, some 
clinicians choose to rely more on clinical response rather than targeting a range of 
concentrations. It has been reported that the majority of patients can achieve satisfactory 
results by adjusting dose based on clinical signs and symptoms.59
Therapeutic index estimation—The therapeutic range of phenobarbital has been well 
established and accepted. However, there are subjects who are successfully treated with 
phenobarbital levels below this range. Furthermore, there are numerous subjects who 
experience AEs despite having serum drug levels within this range, and there does not 
appear to be a significant relationship between drug level and frequency of AEs. Thus, we 
were unable to quantify the therapeutic index of phenobarbital. Studies evaluating the 
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efficacy and safety of phenobarbital are frequently confounded by concomitant treatment 
with other antiepileptic medications. Despite these limitations, treatment strategies adjusting 
dose based on clinical signs and symptoms have been shown to be as successful as strategies 
relying on TDM.
Phenytoin
Safety—AEs associated with phenytoin use usually occur in dose ranges of 200–450 mg 
(Table 1).60–63 The prevalence of AEs with phenytoin use has been shown to be dose-related 
and independent of concomitantly administered medications.64 In one study, 86% of patients 
with toxicity had phenytoin-free levels >2 μg/mL.64
Efficacy—Phenytoin efficacy with mono- and combination therapy was assessed in studies 
using 3 different measures: 1) percentage of patients who had a >50% reduction; 2) 
reduction in total seizures during the study period; and 3) percentage of patients with seizure 
freedom in a specific time period (Table 2).62,65–68
Therapeutic range and drug monitoring—The conventionally accepted therapeutic 
range of phenytoin is 10–20 μg/mL. This therapeutic range was primarily established from 
small, often retrospective studies performed in the 1960s and 1970s combined with clinical 
experience and expert opinion.69 The dose range associated with efficacy and toxicity 
partially overlaps. The available studies evaluating serum phenytoin concentrations and 
seizure control suggest that seizure frequency is dose-related and seizure control is generally 
poor at concentrations <10 μg/mL.70–74 Serum concentrations between 15 and 20 are 
associated with improved seizure control. Although target total phenytoin concentrations of 
10–20 μg/mL have been used in clinical trials, several studies have shown that total 
phenytoin values >20 μg/mL in certain patients may be optimal.70,75
In clinical practice, TDM is often not routinely performed for phenytoin. Levels may be 
checked when patients experience adverse effects or experience break-through seizures. 
There is a large inter-individual variability in the PK of phenytoin. For patients with ongoing 
physiological changes such as pregnancy, decreased renal clearance, decreased hepatic 
function, or microalbuminemia, TDM may be needed.64,71
Therapeutic index estimation—There is considerable overlap in the toxic and 
therapeutic ranges for phenytoin, and TDM is recommended in certain populations. Based 
on available literature, the therapeutic index for phenytoin is approximately 2. The relatively 
low therapeutic index is one criterion that supports NTI classification for phenytoin (Table 
3).
Valproate
Safety—Valproate is generally well-tolerated at doses that produce concentrations that 
effectively reduce seizures (Table 1).76,77 One study evaluating the safety of rapidly infused 
valproate noted that adverse events often occurred around the time of maximal drug 
concentrations.77
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Efficacy—Valproate efficacy was typically studied as a >50% reduction in seizure 
frequency or complete remission within a given time period (Table 2).30,76,78–80 Seizure 
control has been reported across a wide concentration range of 60–800 μmoles/L (8.7–115.4 
ug/mL).30
Therapeutic range and drug monitoring—The therapeutic range of total valproate 
reported on the FDA label for epilepsy is 50–100 μg/mL (4–15 μg/mL unbound), which is 
consistent with published studies that have evaluated valproate efficacy and safety.81 Many 
clinicians perform TDM when adding drugs with potential interactions, when patients 
experience breakthrough seizures or toxicities, or to monitor compliance with therapy. 
However, clinicians do not consistently perform TDM.
Therapeutic index estimation—Valproate concentrations associated with adequate 
reductions in seizure frequency have been shown to vary widely, and there is little overlap 
between the toxic and therapeutic range. Thus, we were not able to estimate the therapeutic 
index. Clinicians do not consistently perform TDM.
DISCUSSION
There is considerable concern among physicians and patients regarding the safety and 
efficacy of generic AEDs.5 The American Academy of Neurology has issued a position 
statement opposing generic substitution of AEDs without attending physician’s approval, 
citing concerns for toxicity and break-through seizures.6 While much of the evidence for 
these concerns is anecdotal, there has been at least one survey study documenting cases in 
which patients who switched to generic AED formulations experienced lower drug levels 
and breakthrough seizures.82 In addition, a large Canadian claims database study compared 
the frequency of switchback rates for AEDs and other drugs in patients who had been 
compulsorily switched to generic formulations.83 In this study, the switchback rates to 
brand-name formulations were higher for both lamotrigine (13%) and valproate (20%) 
compared to non-AED drugs (1.5–2.9%).
If the FDA were to enact tighter bioequivalence standards for generic formulations of certain 
drugs, clinicians and patients could more confidently choose less expensive products, 
leading to health care cost savings. Tighter bioequivalence standards, however, are not 
necessary for drugs that have a wide therapeutic index, because larger variations in patient 
exposure can be well-tolerated. Identification of NTI drugs is therefore key to the 
implementation of new bioequivalence standards.
In our study, we completed a comprehensive literature search to estimate the therapeutic 
index of 5 AEDs, a crucial step towards determining whether these drugs could be classified 
as NTI. We found that the therapeutic index we estimated from the available literature 
supported NTI classification for 1 of the 5 AEDs studied (phenytoin), while 2 other AEDs 
(carbamazepine, lamotrigine) require the evaluation of multiple other factors to determine 
whether they may be classified as NTI. A recent study of generic-to-generic switches in 
epilepsy patients taking different forms of lamotrigine showed bioequivalence of disparate 
lamotrigine products, with no apparent difference in clinical effects.84 For the 2 drugs for 
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which NTI status could not be adequately determined (carbamazepine and lamotrigine), 
TDM is advisable for at least some clinical situations, and there is some concentration-
dependent efficacy and toxicity. Approval of generic formulations of these drugs without 
stringent testing of PK and pharmacodynamics properties could result in unacceptable risk 
of adverse effects or breakthrough seizures. In 2014 and 2015, the FDA updated the 
bioequivalence guidance for phenytoin and carbamazepine to request tighter bioequivalence 
standards for NTI drugs.85
The strengths of our study include a thorough review of all available toxicity and efficacy 
data for 5 AEDs. Based on the compiled information, we calculated therapeutic indices for 
use in classification of most of our drugs of interest. This study represents a proof-of-
concept method that can be replicated to other drug classes to estimate therapeutic indices. 
During the period of brand-name drug exclusivity (5–7 years) when post-marketing data is 
generated, a data review can be performed to estimate the therapeutic index, and to 
potentially support its NTI classification.
Our study is limited by the heterogeneity of the data available in the existing literature; our 
results are based on a wide variety of trials that included different populations, study 
designs, indications, and drug dosages and regimens. In addition, for some drugs, very 
limited data were available from which we were able to draw conclusions. Our search 
methods, while comprehensive, may have led to incomplete retrieval of data. We also did not 
capture clinical practice data, which is an important component required for NTI 
classification. Finally, our estimation of therapeutic index was based on the population 
therapeutic range, which may be wider than that of an individual. Therefore, we may have 
overestimated the therapeutic index that can be applied to an individual. We have also 
included AE data from both titration and maintenance phases, and the therapeutic index may 
differ in different clinical situations. Given these limitations, combining the results of our 
review with other methods of NTI classification, including expert opinion and PK/PD 
modeling, may help determine which drugs should be subjected to more stringent 
bioequivalence criteria. The ideal source of data regarding safety and efficacy of generic 
formulations would be trials in which patients are randomized to continuing on brand-name 
formulations vs. switching to generics, with drug levels collected in patients experiencing 
toxicity. However, the cost of such trials to evaluate all possible NTI drugs is prohibitive. 
Our approach offers a low-cost method of therapeutic index determination. Our results can 
serve as preliminary data for future trials and as guidance for FDA decision-making 
regarding NTI drugs.
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Figure 1. 
Search strategies
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Table 1
Representative drug-related adverse events (AEs) and associated dose ranges
Number of subjects AE Type AE Severity Incidence Range of AED doses
Carbamazepine
91–3011–3,5,6 Somnolence
Decreased appetite
Mild/moderate 8–36%
2%
400–1200 mg/day
91–37815, 16, 18–21 Gastrointestinal Mild/moderate 4–29% 400–2000 mg/day
91–37815–20 Rash Mild/serious 8–32% 200–2000 mg/day
20–23017, 21, 22 Decreased white blood cells Mild Not reported 200–1400 (5–24 mg/kg/day)
Lamotrigine
8 – 33435, 39, 40 Rash Moderate/serious 1%, 3%, 8% 100–500 mg (serious), 100 mg (moderate)
156 – 33437, 40 Stevens-Johnson syndrome Serious 0. 1%, 1% 300–400 mg, 300 mg/day, and 250 mg bid
14136 Grand mal seizures Serious 1% 300–400 mg/day
12638 Diplopia Serious 1% 250 mg
33440 Dizziness Serious 0. 6% 100–500 mg
33440 Blurry vision Serious 0. 6% 100–500 mg
33440 Ataxia Serious 0. 3% 100–500 mg
33440 Nausea Serious 0. 3% 100–500 mg
Phenobarbital
11448 Elevated GGT Mild 58% NR
18–124e-ref 82, e- ref 83 Hypotension NR 11–49% 10–30 mg/kg
1854 Intubation Severe 33% 10–30 mg/kg
10–143 e-ref 71, e- ref 78 Somnolence Mild 30% 8. 3–133. 3 mg/day
14350 Fatigue Mild 21% 8. 3–133. 3 mg/day
Phenytoin
127–15159, 60 Rash Moderate/serious 19% (mild), 8% 
(moderate), 2% 
(serious)
300 mg (serious)
114e-ref 61 Stevens-Johnson syndrome Serious 1% 300 mg
14159 Suicide attempt Serious 1% 300 mg
67e-ref 62 Myalgia Moderate 2% 200–450 mg
Valproate
112e-ref 76 Somnolence Mild 10–15% 1. 5–3. 0 mg/kg/min
112e-ref 76 Dizziness Mild 8–10% 1. 5–3. 0 mg/kg/min
112e-ref 76 Nausea Mild/moderate 8–10% 1. 5–3. 0 mg/kg/min
112e-ref 76 Paresthesia Mild 8% 1. 5–3. 0 mg/kg/min
GGT: gamma-glutamyl transpeptidase
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Table 2
Representative range of antiepileptic drug (AED) doses in studies with successful monotherapy.
Number of subjects Outcome measure Efficacy results Dose range
Carbamazepine
30014 Seizure-free at 26 weeks 75% 400–1200 mg
23017 Withdrawn from treatment at <52 weeks 42% 200–1400 mg
12918 Seizure-free at 48 weeks 38% 300–1400 mg
23620 Seizure-free at 48–96 weeks 34% Mean: 722 mg
10121 Withdrawn from treatment at <36 months 45% 600 mg
Lamotrigine
24942 Seizure-free at 12 months 61% 25–600 mg
22619 Seizure-free at 7 weeks 60% 100–200 mg
15637 Remaining on monotherapy 56% 100–500 mg
22243 Seizure-free at 1 year 89% 50–150 mg
13118 Seizure-free at 40 weeks 26% 100–300 mg
Phenobarbital
12453 Resolution of all clinical and electrical evidence of seizure 
activity within 20 minutes of start of infusion
58% 15 mg/kg
1854 Resolution of status epilepticus 61% 5–23 mg/kg
856 Fewer seizures than clorazepate comparator 50% 148 ± 21. 8 mg/day
Phenytoin
114e-ref 61 >50% seizure reduction 57% 200–300 mg
50e-ref 64 Seizure-free at 6 months 53% 3–5 mg/kg
26e-ref 65 Seizure-free at 12–41 months 76% 200–300 mg
37e-ref 66 >50% reduction in seizure frequency at 14–24 months 82% 300 mg
95e-ref 67 Seizure-free at 10 months 24% 300 mg (mode)
Valproate
238e-ref 75 Time to treatment failure Valproate significantly better 
than topiramate, but no 
significant difference 
between valproate and 
lamotrigine
200–3000 mg
16e-ref 77 Seizure-free at 12 months 25% 1000–2000 mg
6430 >50% reduction in seizure frequency at >3 months 80% 600 mg (adults); 5–10 
mg/kg (children)
13e-ref 78 Reduction in seizure frequency A statistically significant 
difference was observed 
between VPA levels and 
seizure frequency. The 
relationship was curvilinear.
300–4000 mg
10e-ref 79 >50% reduction in seizure frequency at 12 weeks 50% 900 mg
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